Health Canada is currently reviewing nine submissions for generic versions of popular obesity medications, potentially paving the way for lower prices this summer. The focus is...
Novo Nordisk has announced significant price reductions for its obesity treatments, Wegovy and Ozempic, in an effort to compete more effectively against rival Eli Lilly, which...
Novo Nordisk A/S has revised its 2025 sales forecast for the fourth time in 2023, attributing the adjustment to weaker-than-anticipated demand for its leading medications, Wegovy...
Recent research from the University of Utah has unveiled a promising method for enhancing glucagon-like peptide-1 (GLP-1) agonists, potentially paving the way for a new generation...
